Adil E. Bharucha, MD
What is the safety of proton-pump inhibitors (PPIs) taken during early pregnancy in terms of fetal outcome?
Included studies examined exposure to PPIs during at least the first trimester of pregnancy, included a comparison group not exposed to PPIs, and described fetal outcomes. Outcomes were congenital malformations, spontaneous abortion, and preterm delivery.
MEDLINE, EMBASE/Excerpta Medica, International Pharmaceutical Abstracts, EBM Reviews, and CINAHL (all to July 2008); and references were searched for published original research articles or abstracts. 4 prospective cohort studies (n = 1901) and 3 retrospective cohort studies (n = 133 039) were included. Average quality score was fair (69%).
Use of PPIs during the first trimester of pregnancy was not associated with increased risk for congenital malformations, spontaneous abortion, or preterm delivery (Table). Omeprazole was not associated with increased risk for congenital malformations.
Use of proton-pump inhibitors during the first trimester of pregnancy was not associated with increased risk for congenital malformations, spontaneous abortion, or preterm delivery.
Fetal outcomes after exposure to proton pump inhibitors (PPIs) during the first trimester of pregnancy
*CI defined in Glossary. Based on a random-effects model.
Bharucha AE. Review: PPI use in pregnancy was not associated with increased congenital malformations, spontaneous abortion, or preterm delivery. Ann Intern Med. 2009;151:JC5–14. doi: 10.7326/0003-4819-151-10-200911170-02014
Download citation file:
© 2019
Published: Ann Intern Med. 2009;151(10):JC5-14.
DOI: 10.7326/0003-4819-151-10-200911170-02014
Esophageal Disorders, Gastroenterology/Hepatology, Gastroesophageal Reflux Disease, Peptic Disease, Prevention/Screening.
Results provided by: